Academic Foundation Trainee, The Royal Wolverhampton NHS Trust, England, UK.
General and Oncoplastic Breast Surgery Registrar, Gartnavel General Hospital, Greater Glasgow and Clyde, NHS Scotland, UK.
Eur J Surg Oncol. 2021 Aug;47(8):1883-1890. doi: 10.1016/j.ejso.2021.03.249. Epub 2021 Apr 13.
The use of chest wall perforator flaps (CWPFs) following breast conservation surgery for breast cancer has become a useful tool in the armamentarium of the oncoplastic breast surgeon, however robust evidence for the technique is lacking. The aim of this study was to conduct a systematic review appraising the current evidence for the use of CWPFs, evaluating clinical, oncological and cosmetic outcomes. A PRISMA-compliant systematic review, with PROSPERO published protocol a priori and search of all relevant database and trial registries between 1990 to July 2020. Eleven studies amounting to 432 cases were reviewed and considered to be at high risk of bias due to small sample size, selective outcome reporting and selection bias. Heterogeneity due to lack of consensus of outcome measures prevented meaningful analysis. Fifty-two (12.3%) clinical complications were recorded: seroma (n = 9; 2.1%), fat necrosis (n = 9; 2.4%), haematoma (n = 8; 1.9%), infection (n = 9; 2.1%), and flap necrosis (n = 9; 2.1%). Thirty-four (10.8%) patients had an involved positive margin, 29 patients underwent re-excision (9.3%) and four underwent completion mastectomy (1.3%). One local recurrence and six distant recurrences were observed during a mean follow up of 21 months (1-49). A pooled patient cosmetic satisfaction descriptor of good or excellent was described in 93% of cases. CWPFs are a safe method of partial breast reconstruction following BCS. They are associated with a low complication rate, acceptable short-term oncological outcomes and satisfactory cosmetic outcome. There is a relative paucity in quality of data in this field and larger prospective studies are needed to investigate outcomes further.
胸壁穿支皮瓣(CWPF)在乳腺癌保乳手术后的应用已成为整形乳房外科医生的有用工具,但该技术缺乏强有力的证据。本研究旨在对 CWPF 应用的现有证据进行系统评价,评估临床、肿瘤学和美容结果。这是一项符合 PRISMA 标准的系统评价,采用 PROSPERO 预先发表的方案,并在 1990 年至 2020 年 7 月期间对所有相关数据库和试验登记处进行了搜索。共回顾了 11 项研究,共计 432 例,由于样本量小、选择性结果报告和选择偏倚,这些研究被认为存在高偏倚风险。由于缺乏对结果测量的共识,导致无法进行有意义的分析,存在异质性。记录了 52 例(12.3%)临床并发症:血清肿(n=9;2.1%)、脂肪坏死(n=9;2.4%)、血肿(n=8;1.9%)、感染(n=9;2.1%)和皮瓣坏死(n=9;2.1%)。34 例(10.8%)患者有阳性切缘受累,29 例患者接受了再次切除术(9.3%),4 例患者接受了全乳切除术(1.3%)。在平均 21 个月(1-49 个月)的随访中,观察到 1 例局部复发和 6 例远处复发。93%的病例描述了患者美容满意度良好或优秀。CWPF 是保乳手术后部分乳房重建的一种安全方法。它们与低并发症发生率、可接受的短期肿瘤学结果和满意的美容结果相关。该领域数据质量相对较少,需要进一步开展更大规模的前瞻性研究以调查结果。